Safety Assessment

From complete IND-enabling programs to stand-alone assessments, our Safety Assessment team provides a full range of in vivo and in vitro testing services and regulatory support to comply with worldwide regulatory restrictions for the nonclinical development of pharmaceuticals, medical devices and animal health products as well as chemicals, agrochemicals, and biocides. Our scientific and regulatory staff work with clients to develop and execute individual studies or customized testing programs to ensure that drug safety and efficacy assessments are conducted in the most efficient manner.

Talk to an Expert


Photo of nurse with patient.

What's a week worth to your Patients?

As part of our commitment to accelerate your drug development program, we’ve condensed our reporting timeline to nine weeks for GLP-IND-enabling studies (up to three months in duration without peer review, 11 weeks for studies with peer review). Give your therapy the best chance to get to patients first. Choose a partner who delivers your safety data faster.

Accelerate your Therapy


IND-Enabling Studies Toolbox

Planning for your IND-enabling studies requires the right partner to support your program, preparing the proper test articles, and planning your submissions. Make sure you choose a partner that can quickly mitigate any risks, deliver reports quickly, and offer actionable insights to submit your investigational new drug application on time.

Get the tools

American College of Toxicology Annual Meeting attendee using laptop

American College of Toxicology (ACT) Annual Meeting

Even though we may not have the opportunity to meet you in person, we are proud to be an active participant in this year's virtual American College of Toxicology (ACT) Annual Meeting. Our experts are part of the extensive program offered by ACT this year, presenting continuing education sessions, symposiums, exhibitor sessions, and posters throughout the week.

Learn More